|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||66.93 / 83.58|
Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.
Novartis holds a 36.5% stake in the healthcare company.
Analysts estimate total revenue will fall 6.9% to $3.53 billion in the quarter due to the loss of patent exclusivity on some drugs and divestitures of major business lines.
Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.
Biotech investors should keep a close eye on the progress in this huge potential market.
Another big rally made for a day of milestones: the Dow and S&P 500 enjoyed their best back-to-back gains of the year, while the Nasdaq scored a new record.
Estimates for erenumab annual sales run as high as $2.3 billion.
Better-than-expected earnings from industry leaders including Caterpillar and McDonald's push the Dow to log triple-digit gains for the second day in a row, its best two-day stretch of the year.
A stream of positive earnings reports keep stocks on the rise on Tuesday with the Dow Jones Industrial Average logging triple-digit gains for the second day in a row.
Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid.
Novartis shares led gainers in Zurich Tuesday after the pharmaceuticals group held on to full year earnings targets and narrowly beast analysts' forecasts for first quarter earnings.
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Earnings and hopes for a tax plan help lift the markets. Portfolio moves include exiting a utility position.
The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite Pharma's competing "CAR-T" KTE-C19 in the same DLBCL patients.
The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite's competing 'CAR-T' KTE-C19 in the same DLBCL patients.
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
The maker of the EpiPen seems incapable of overcoming its troubles.
The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.
Novartis shares fell after it said a potentially key cardiovascular treatment had failed a global clinical trial, putting doubt over the group's ability to offset slowing heart disease drug sales.
The Democrats aim to generate public opposition to repeal by offering amendments that highlight fears the GOP plan will result in more expensive insurance and fewer people with coverage.
Stocks fall for a second day on Tuesday, the first back-to-back decline since January, as a selloff in health care spoils attempts by the market to push higher.
Stocks slump Tuesday as a selloff in health care spoils an attempt by the market to push higher.
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
Stocks are in flux on Tuesday as Donald Trump makes vague promises to lower drug prices, while Republicans unveil their bill to tackle health care reform.
European healthcare stocks fell Tuesday after President Donald Trump reiterated a vow to reduce drug prices in the United States.
President Trump's socially conservative administration has vowed to crack down on marijuana, but here's why pot investors shouldn't worry.